LUND, Sweden, Jan. 19, 2023 /PRNewswire/ -- Immunovia (Nasdaq
Stockholm: IMMNOV), the diagnostics company that has launched the
world's first blood test dedicated to the early detection of
pancreatic cancer, today announced it is realigning its Swedish
operations with its strategic priorities to drive R&D
productivity and focus on the US commercialization of the IMMray™
PanCan-d test.
In October 2022, Immunovia
announced a research collaboration partnership with the Swiss
diagnostic company Proteomedix. The partnership capitalizes on the
combined expertise of two leading innovators in proteomics-based
diagnostics. Following the early experience of the collaboration
Immunovia has been able to better understand the opportunities
available to the Company and has determined that the in-house need
for R&D capability has changed. As a result, Immunovia has
initiated a union consultation process with the aim of reducing the
number of employees within R&D and Operations in
Lund.
"Immunovia has entered a new phase with an increased focus on
the commercialization of our IMMray™ PanCan-d test in the U.S.,
while maximizing our R&D productivity. The R&D and
Operations teams in Lund have
delivered very strong results in developing the IMMray™ PanCan-d
test. At the same time, Immunovia is in the early stages of
commercial execution, and the scope of the in-house R&D and
Operations needs have changed. We are working to create a smooth
transition for the employees affected by this change," said
Philipp Mathieu, CEO and President
of Immunovia.
Immunovia has initiated a consultation process with relevant
Swedish unions to create the best possible transition for the
affected employees. The Company will provide an update once the
consultation process is concluded.
For more information, please contact:
Philipp Mathieu,
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
The following files are available for download:
https://mb.cision.com/Main/13121/3699907/1790551.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-realigning-swedish-operations-with-strategic-priorities-and-its-focus-on-the-us-commercialization-of-the-immray-pancan-d-test-301725619.html